Tag: Enveric Biosciences

Debra BorchardtFebruary 23, 2024

Enveric Biosciences (NASDAQ: ENVB) is selling one of its cancer-related patent portfolios for an undisclosed amount. Enveric said it plans to continue to focus and invest in the development of its lead candidates EB-003, a first-in-class neuroplastogen designed to eliminate hallucinations, and EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin. “We […]

Debra BorchardtSeptember 20, 2023

Enveric Biosciences (NASDAQ: ENVB) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company’s EVM301 Series of molecules being developed as potential treatments for mental health disorders. “Our EVM301 Series consists of small molecule therapies designed with the intent […]

Debra BorchardtJuly 24, 2023

Enveric Biosciences (NASDAQ: ENVB) announced the successful completion of preclinical ADME and toxicology studies for its lead candidate EB-373. EB-373 EB-373, is defined as a New Chemical Entity or NCE. According to the company it is designed as a next-generation proprietary psilocin prodrug and developed leveraging the company’s Psybrary drug discovery platform to target anxiety […]

StaffApril 4, 2022

Enveric Biosciences (NASDAQ: ENVB), a neuroscience company developing next-generation, psychedelic-inspired mental health medicines, announces yet another filing of a provisional patent application based on new discoveries by the Company. This adds to their”Psybrary”. The application describes more than 100 novel individual molecules and, if the broadest claims are allowed, could protect more than 10,000 possible […]

Dave HodesJanuary 24, 2022

An emerging trend in some bioscience startups is the development of both cannabis and psychedelics products. One such company is Enveric Biosciences, headquartered in Naples, Florida, which hopes to leverage psychedelics-derived molecules for the mind and create synthetic cannabinoids for the body in the treatment of cancer. Enveric Biosciences focuses on synthesizing novel, tailored and […]

StaffDecember 15, 2021

Psychedelic biotech company Enveric Biosciences (NASDAQ: ENVB) announced the appointment of Bob Dagher, MD, as Chief Medical Officer, effective immediately. Robert Wilkins, MD, stepped down from his role of Chief Medical Officer on November 29th, 2021. Prior to joining Enveric, Dr. Dagher served as the Chief Medical Officer at WCG MedAvante-ProPhase where he led the clinical […]

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.